ASH Annual Meeting 2022 - summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for the biggest events of the year in the world of haematology – the American Society of Hematology (ASH) annual meeting. More...
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25 years since the seminal 1998 Journal of Clinical Oncology paper (1) upon which Rituximab was approved for relapsed/refractory...
Enhancing Fas-mediated Bystander Killing of Follicular Lymphoma to prevent post-immunotherapy antigen escape. Follicular lymphoma (FL) is generally considered incurable, however, newer T-cell mediated therapies including bispecific Abs (bsAbs) and CAR-T cells induce...
Educational workshop covering targeted therapies for FL With the ever-evolving landscape of targeted and cellular therapies, how can the most recent advances be incorporated into follicular lymphoma patient care? Which diagnostic and prognostic features are important...
The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in follicular lymphoma that the Precision Medicine Programme (PMP) could help to address....
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
